RxDoctor Payments Data

Barbara Murphy, MD

Medical Oncology · Nashville, TNNPI 1285733618

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $29,075 of the $31,209 with a category attached, or 93.2%. 5 manufacturers reported payments, led by Merck at 48.6% of the total. Reporting peaked in 2020 at $15,431 and has fallen 99.6% since, to $65 in 2025.

$31,209in general payments, 2019–2025

Across 28 payments — averaging $1114.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$15K
  • Amgen$9K
  • Tactile Systems Technology Inc$4K
  • Regeneron Healthcare Solutions, Inc.$3K
  • EMD Serono, Inc.$67
$783,392in research payments, 2019–2025

Across 63 payments — averaging $12,435 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Tactile Systems Technology Inc$779K
  • Siemens Medical Solutions USA, Inc.$4K

What the payments were for

  • Consulting fees$29,07593%
  • Travel & lodging$1,3674%
  • Food & beverage$7672%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,209 in reported general payments places this provider in the 70th percentile of 101 medical oncology providers in Tennessee.

See all medical oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$68,149
Medicare patients
200
Services billed
529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LenvimaLenvatinib Mesylate20$452,635
Xtampza ErOxycodone Myristate32$100,774
OxycontinOxycodone Hcl35$73,205
Oxycodone Hcl232$13,254
Fentanyl44$12,299
EliquisApixaban12$11,484
Gabapentin193$5,667
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen44$2,616
Pentoxifylline20$1,824
Morphine Sulfate ErMorphine Sulfate38$1,785
Ondansetron Hcl35$1,366
Lidocaine22$1,328
Hydromorphone Hcl16$1,172
Pilocarpine Hcl19$961
Naloxone Hcl18$955

Paid to pharmacies, not to this prescriber.

Other medical oncology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →